Background. Haemodiafiltration (HDF), by successfully removing the larger solutes and protein-bound compounds, may offer a feasible approach to improve dialysis outcomes. Recently, three large, randomized, controlled trials have tested this hypothesis, but only one showed an improved survival associated with HDF treatment, when compared with haemodialysis (HD). Methods. This is a retrospective analysis of the entire Romanian dialysed population from the European Clinical Database (EUCLID) Fresenius Medical Care Database. We conducted two types of analysis. First, we used an intention-to-treat approach including all patients who were in dialysis (either HDF or HD) at 1 March 2010-'prevalent cohort analysis'. We then considered only the incident patients who started dialysis (either HDF or HD) after 1 March 2010-'incident cohort analysis'. In both analyses, patients were followed until 31 April 2013. Results. In the prevalent cohort, we included 1546 patients who were already performing dialysis at the first time point-1322 on HD and 224 on HDF. When compared with HD, HDF treatment was associated with reduced mortality in both univariate and multivariate survival analysis (HR = 0.67, 95% CI 0.46−0.96 and HR = 0.58, 95% CI 0.36−0.93, respectively). In the incident cohort, 2447 patients started dialysis (2181 HD and 266 HDF) during the observation period. Patients in the HDF group maintained a reduced risk for all-cause mortality (HR = 0.20, 95% CI 0.11−0.38 for the univariate and HR = 0.24, 95% CI 0.13−0.46 for the fully adjusted model).
I N T RO D U C T I O N
Although significant advances are being made in the understanding of uraemic toxins and despite improvements in the complex management of dialysed patients, morbidity and mortality rates remain unacceptably high. According to the 2013 US Renal Data System annual data report, adjusted rates of all-cause mortality are 6.5-7.9 times greater for dialysis patients than for age and gender matched individuals from the general population (http://www.usrds.org/atlas. aspx). In Europe, the 2011 Annual Report from the European Renal Association-European Dialysis and Transplant Association Registry [1] shows a 2-year survival probability for incident dialysis patients of only 71.6%. This increased risk of mortality can in part be explained by a number of risk factors unique to uraemia itself, including mineral metabolism disorders, a chronic inflammatory status and accumulation of uraemic toxins.
Larger solutes and protein-bound compound seem to be particularly related to deleterious biological and clinical effects but are difficult to remove by standard haemodialysis (HD) [2, 3] . Successful removal [4−7] of these larger solutes and protein-bound compounds by haemodiafiltration (HDF) may therefore offer a viable approach to improve dialysis outcomes.
This hypothesis had been tested in a number of trials. In uncontrolled studies, convective dialysis therapies were shown to decrease mortality [4] [5] [6] [7] [8] . Three large randomized controlled trials have recently been published [9] [10] [11] , but with the exception of the Estudio de Supervivencia de Hemodiafiltracion On-Line (ESHOL) study [11] , they failed to demonstrate an improvement in survival associated with HDF treatment, when compared with HD. Two meta-analyses [12, 13] reported different results on all-cause mortality, but both confirmed a reduced cardiovascular mortality for HDF-treated patients.
In Romania, reporting to the Romanian Renal Registry (RRR) is compulsory. According to the RRR, the total number of dialysed patients (HD and HDF) increased from 8068 in 2010 ( point prevalence of 372 per million population) to 9551 patients in 2012 ( point prevalence of 502 per million population). On 19 November 2009, the Romanian National Health System nr 967/2009 Law was released [14] . This document regulated national indications for HDF treatment initiation and reimbursement, thus creating a unique scenario to analyse the results and impact of HDF. In this analysis of the dialysed Romanian population from the European Clinical Database (EUCLID) Fresenius Medical Care Database, we aimed to evaluate the impact of HDF treatment on mortality, following the implementation of the aforementioned law.
M AT E R I A L S A N D M E T H O D S

Patients
The 967/2009 Law was issued by the President of the Romanian National Health System on 19 November 2009. This document stated the following indications for HDF treatment initiation:
• patients in which dialysis efficiency targets (eKt/V ≥ 1.4 or phosphorus ≤5.5 mg/dL) are not reached for three consecutive months; • young patients who could have survival benefits from dialysis, but have contraindications for kidney transplantation; • patients with uraemic neuropathy;
• patients with cardiovascular comorbidities or diabetes.
We retrospectively evaluated patients from the Romanian Fresenius Medical Care EUCLID Database and conducted two types of analyses.
First, we used an intention-to-treat approach including all patients who were in dialysis at 1 March 2010-i.e. 3 months after the release of this law-'prevalent cohort analysis' (Figure 1 ). Patients were excluded for the following reasons: dialysis vintage <3 months, recovery or renal function, age <18 years. This prevalent cohort was followed until April 2013.
To avoid the carryover effect and the impact of previous dialysis burden, we then analysed only the incident patients who started dialysis (either HDF or HD) after 1 March 2010 and were followed until 31 April 2013 (Figure 1 )-the 'incident cohort analysis'. Similar to a previous report by Vilar et al. [6] , we defined the HDF group as those patients who had at least 50% of all dialysis sessions using HDF. Patients were excluded for the following reasons: dialysis survival or time until outcome analysis <3 months, treatment stopped or recovery or renal function, age <18 years.
Data gathering
For the prevalent patients, we collected: 
O R I G I N A L A R T I C L E
H D F a n d m o r t a l i t y : t h e R o m a n i a n e x p e r i e n c e calcium, phosphorus and parathyroid hormone), anaemia parameters [haemoglobin and ferritin levels, transferrin saturation, usage of erythropoiesis-stimulating agents (ESA) and iron supplementation], nutrition and inflammation parameters [serum albumin, C reactive protein (CRP)] were determined on March 2010.
For the incident patients, we collected demographic data and comorbidities at dialysis initiation, as well as treatment modality parameters (HDF or HD) for each dialysis session from 1 March 2010 until 31 April 2013. For both analyses, patients were censored by the date of kidney transplantation, treatment cessation or transfer to a non-Fresenius dialysis unit.
Dialysis treatment
All patients were treated with polysulfone high flux membranes. All treatments, either HD or HDF, were performed with ultrapure water. Water quality was regularly monitored to ensure ultrapure dialysis fluids (total viable count <0.1 cfl/mL and endotoxin level <0.03 EU/mL). All dialysis were acetate free. The basic dialysis fluid composition varied: 138−140 mmol/L Na + , 2 mmol/L K + , 1.25
, 32 mmol/L HCO 3 À , 0 −1 g/L glucose and 6 mmol/L acetate.
Statistical analysis
Data are presented as median with inter-quartile range (IR) or frequency, as appropriate. Comparisons between groups were made using the Mann-Whitney test for non-parametric data or the chi-square test for categorical data. Survival between groups was compared using the Kaplan-Meier with log-rank test for statistical significance and Cox analysis. In the prevalent cohort for the multivariable Cox analysis, we used different adjusting models: in Model 1, we adjusted for age, gender, Charlson index score, dialysis vintage; in Model 2 CRP, albumin, systolic blood pressure were added to Model 1; in Model 3, we adjusted for all variables used in the previous two models. In the incident cohort, the enter method was applied for multivariable Cox analysis. A P-value of <0.05 was considered as significant.
Because the patients were not randomly assigned to receive HDF treatment, we also performed an analysis using propensity score matching to adjust for differences in baseline characteristics. We calculated the propensity score for chronic kidney disease for each patient using a multivariable logistic regression model in which treatment (HD or HDF) was the outcome variable. For the prevalent patients, sex, age, dialysis vintage, Charlson score, CAD, CHF, PVD, CVD, diabetes, CRP, albumin, haemoglobin, ferritin, ESA therapy, serum calcium, phosphorus and iPTH levels, eKt/V, Qb and weekly time were considered predictors for the outcome of interest. For the incident cohort, sex, age, CAD, diabetes and Charlson score were used as predictors. All two-way interactions between these variables were included in the scores. After estimation of a distinct propensity score, patients in the HDF group were matched without replacement, in a 1:2 ratio, to patients in the HD group in accordance with the nearest-neighbour-matching algorithm (a calliper width equal to 0.2 of the standard deviation of the logit score was used). Patients without a match were excluded from the analysis.
All calculations were made using SPSS for Windows, version 19.0.1, Chicago, IL, USA with SPSS R plug-in.
R E S U LT S
Prevalent patient analysis A total of 1546 patients were already performing dialysis at the first time point-March 2010-1322 on HD and 224 on HDF, with a considerable dialysis vintage: 44 (16−99) months. In the HDF group, there were more men, and as expected from the law requirements, a higher prevalence of diabetes, a longer dialysis vintage, and more patients with a Charlson index score of at least 3 (Table 1) . At the same time, patients in this group were less inflamed and had a better anaemia control (higher haemoglobin and ferritin levels with a lower usage of erythropoietin stimulating agents)- Table 2 . Bold values are statistically significant. BMI, body mass index; CAD, coronary artery disease; CHF, chronic heart failure; CVD, cerebrovascular disease; DBP, diastolic blood pressure; HD, haemodialysis; HDF, haemodiafiltration; HR, heart rate; PVD, peripheral vascular disease; SBP, systolic blood pressure.
Between 2010 and 2013, HDF patients had a higher blood flow rate and higher blood volume processed compared with HD controls (Table 3 ). The median convective volume achieved was 22.2 (IR = 18.1−34.1) L/HDF session.
Patients in the HD group had a higher incidence of death (Table 1, Figure 2) . In multivariate analysis, the HDF treatment maintained an independent association with reduced mortality (Table 4 ). There was no association between the delivered convection volume and mortality risk.
After propensity score matching, 221 HDF-treated patients were successfully matched to 431 HD-treated patients. Three patients from the HDF group were excluded because of the lack of an appropriate match. After matching, there were no significant clinical differences between the patients in the two groups ( Supplementary Tables 1-3 ). Even after this adjustment, patients in the HDF group were associated with a better survival (HR = 0.62, 95% CI 0.42-0.93, P = 0.02) than patients in the HD group.
Finally, we conducted a sensitivity analysis in the matched cohort to identify if HDF treatment improves survival in different subgroups on the basis of the following variables, which were pre-specified as indicators for HDF treatment by the Romanian law: age, diabetes, Charlson comorbidity index score and CHF (as markers of general and cardiovascular health), phosphorus and eKt/V (Figure 3) . The risk estimates were calculated in all subgroups arising from these variables, using the original categories for nominal variables and the cut-offs provided by the Romanian law or the median for continuous variables. The statistical tests for interaction were not significant except for age (Figure 3) . There was also a trend for an improved survival associated with HDF treatment in patients with a Charlson score of <3.
Incident patients analysis
To confirm a potential beneficial effect of HDF, not related to the carryover effect of the previous dialysis history, inherent 
O R I G I N A L A R T I C L E
H D F a n d m o r t a l i t y : t h e R o m a n i a n e x p e r i e n c e to any analysis of prevalent cases we analysed only those patients who started dialysis after 1 March 2010. From a total of 3329 patients we excluded 882 patients due to:
• dialysis survival or time until censoring <3 months (N = 727),
• treatment withdrawal (N = 67),
• recovery of renal function (N = 25),
• age <18 years (N = 63).
The median percentage of actually performed HDF session was 0 (IR 0-2.4), with 1761 patients performing only HD (71.9%). Again, as expected from the pre-specified law requirements, patients in the HDF group were younger and a higher prevalence of male gender, diabetes, comorbidities (Table 5) . Fewer deaths (Table 5) were recorded in the HDF group. Patients in the HDF group had a lower mortality than those in the HD treatment group (Figure 4 and Table 6 ). In univariate analysis only age and diabetes were also associated with death. In multivariate Cox analysis, using all available variables in the model, the type of renal replacement therapy (RRT) maintained an association with mortality risk (Table 6) .
After propensity score matching, only one incident patient was lost because of the lack of an appropriate match, so 265 HDF-treated patients were successfully matched to 530 HD-treated patients. As shown in Supplementary Table 4 , after matching there were no differences in the variables evaluated in the study between the two groups of patients. In the matched cohort, HDF-treated patients maintained an association with an improved survival (HR = 0.22, 95% CI 0.11-0.43, P = 0.02). F I G U R E 3 : Sensitivity analyses for the main outcome showing HRs (95% CIs) for the intervention based on relevant variables that were prespecified as indicators for HDF treatment by the Romanian law ( prevalent cohort).
D I S C U S S I O N
Our retrospective analysis of the Romanian EUCLID database suggests that, compared with standard HD, HDF treatment is associated with improved survival in a dialysis subpopulation with a more severe comorbidity profile, even after correction for different confounding variables. Serious differences between the number of patients in HDF and HD exist as per study design; our study was a real-life analysis of what happened following compulsory introduction of nationwide rules for the use of HDF in Romania and this provided a unique opportunity since for incident patients the scenario was as close as possible to a prospectively planned study, with all real-life advantages and minus all study-life biases.
Several studies, both observational and randomized, have suggested a survival benefit for HDF-treated patients, when compared with those treated with HD. Canaud et al. [4] showed that the use of HDF with > 15 L per session replacement fluid was associated, even after multiple adjustments, with a 35% lower mortality risk. These results were later reinforced by other observational studies including cohorts from the USA [5] , UK [6] , Italy [7] or the Euclid FMC ® database [8] .
More recently, the results of three large randomized controlled trials were published. Unexpectedly, the CONvective TRAnsport STudy (CONTRAST) [9] and the Turkish HDF study [10] did not find a significant difference in all-cause mortality between HDF and HD. By comparison, the ESHOL [11] , the largest RCT with the highest achieved convection volumes, reported superiority of HDF over HD with respect to all-cause and cardiovascular mortality.
The issue of the effect of HDF treatment on mortality still remains open to debate as two recent meta-analyses yielded different final results. Nistor et al. [13] indicated that convective therapy has little or no effect on all-cause mortality (RR 0.87, 95% CI 0.70-1.07), while Mostovaya et al. [14] found that mortality was significantly lower in the HDF group (RR: 0.84; 95% CI 0.73-0.96). Importantly, both meta-analyses showed that convective therapy might reduce cardiovascular mortality.
Our study offers a unique and valuable perspective since a nationwide adopted law strictly regulated, after 2010, the type of patients who would be treated by HDF. This was adopted following: (i) advice from a group of experts that scrutinized the existing literature at that date and (ii) financial constraints that precluded widespread reimbursement for HDF performed irrespective of baseline patient characteristics. As a consequence, the law favoured the progressive inclusion of significantly sicker patients in the HDF treatment category. This offered a particular scientific opportunity, since usually recruitment in F I G U R E 4 : Kaplan-Meier survival analysis for all-cause mortality in HDF (≥50% dialysis sessions) versus HD groups (incident cohort). HD, haemodialysis; HDF, haemodiafiltration. 
O R I G I N A L A R T I C L E
H D F a n d m o r t a l i t y : t h e R o m a n i a n e x p e r i e n c e randomized studies or in cohorts such as DOPPS tends to include patients with a better survival probability. Furthermore, the fixed inclusion criteria coupled with the advantages of compulsory electronic data capture (EUCLID system) offered a superior opportunity to test the null hypothesis, compared with classical retrospective observational cohorts. Our study suggests that HDF may confer potential advantages over standard HD in both incident and prevalent patients. In a similarly conducted study, Vilar et al. [6] suggested that predominant HDF treatment (by definition >50% of all dialysis sessions) was associated with a 55% reduction in the risk of death after correction for confounding variables. Taking into account that the two populations are similar, with small differences regarding the number of patients included and the period of follow-up, the higher improvement in survival observed in our cohort (of almost 70%) is probably the result of the HDF technique used across different periods. Indeed, more recently, Imamović et al. [15] showed a similar survival effect in incident patients treated with high-volume HDF, when compared with high flux HD. However, we acknowledge the fact that there could have been other unmeasured confounders that could have significantly influenced our final results.
The better survival observed in incident HDF-treated patients compared with prevalent HDF-treated patients raises another possibility: the beneficial effects HDF might indeed be higher in incident rather than in prevalent patients. This issue remains still to be fully settled, since so far there are no large randomized trials comparing HDF with HD in incident patients.
The baseline median convective volume was 22.2 L/session, higher than that achieved in the CONTRAST Study, but lower than that from the ESHOL Study, and in our analysis it was not associated with mortality risk. This is in contrast with the findings from the three RCT, where in all post hoc analyses an association between higher convection volumes and better survival was found. Although this dose-effect relation is promising, it should be interpreted with caution, as these post hoc analyses must be viewed as cohort analyses and, therefore, adequate multivariable adjustments should be made to reduce potential confounding [14] . In addition, a recent meta-analysis using univariate meta-regression analysis found no effect of achieved convection volume on all-cause mortality [13] .
Our study has limitations and strengths. First, although we used different approaches to analyse the impact of HDF treatment, this is a retrospective observational study and no causeeffect relation can be definitely considered. Secondly, although our study included a large number of patients, these patients were younger with fewer comorbidities and from a country with one of the greatest survival rates in the world [16, 17] , making it difficult to generalize our results to the entire European dialysed population. Thirdly, we were not able to evaluate different cause of mortality so the effect of HDF treatment on cardiovascular mortality could not be evaluated. Fourthly, we were unable to account for a carryover effect of the previous HDF treatment in our prevalent cohort. Also, we were not able to include data about time of the initial referral, a known factor associated with survival. We tried to overcome this issue by excluding patients who performed RRT for <90 days, and we acknowledge that the impact of the early/late referral on survival could surpass this time limit [18] .
CO N C L U S I O N S
This study suggests that HDF treatment could reduce all-cause mortality in incident and prevalent patients even after correction for different confounders. Interestingly, an additional survival benefit could be observed in incident patients. These findings are interesting, but need confirmation in larger randomized trials.
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